Lipocine Inc. Files 8-K for Corporate Updates
Ticker: LPCN · Form: 8-K · Filed: 2024-11-05T00:00:00.000Z
Sentiment: neutral
Topics: corporate-filing, sec-filing, 8-k
Related Tickers: LPCN
TL;DR
Lipocine Inc. (LPCN) filed an 8-K on Nov 5, 2024, for corporate events. No specific details yet.
AI Summary
Lipocine Inc. filed an 8-K on November 5, 2024, reporting other events and financial statements. The company, incorporated in Delaware with its principal executive offices in Salt Lake City, Utah, previously operated under the name Marathon Bar Corp until November 30, 2011. The filing does not detail specific transactions or financial figures but serves as a notification of corporate events.
Why It Matters
This filing indicates Lipocine Inc. is making official disclosures to the SEC regarding its corporate activities, which could include significant business developments or financial reporting.
Risk Assessment
Risk Level: low — The filing is a standard corporate disclosure and does not contain information that inherently increases risk.
Key Players & Entities
- Lipocine Inc. (company) — Registrant
- Marathon Bar Corp (company) — Former company name
- November 5, 2024 (date) — Date of report
- November 30, 2011 (date) — Date of name change
- Delaware (jurisdiction) — State of incorporation
- Salt Lake City, Utah (location) — Principal executive offices
FAQ
What specific 'Other Events' are being reported by Lipocine Inc. in this 8-K filing?
The provided text of the 8-K filing does not specify the details of the 'Other Events' beyond listing it as an item of information.
What is the significance of the 'Financial Statements and Exhibits' being listed as an item of information?
This indicates that the filing includes or references financial statements and other exhibits, which are typically part of regular SEC reporting or specific corporate actions.
When did Lipocine Inc. change its name from Marathon Bar Corp?
Lipocine Inc. changed its name from Marathon Bar Corp on November 30, 2011.
Where are Lipocine Inc.'s principal executive offices located?
Lipocine Inc.'s principal executive offices are located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah.
What is the SEC file number for Lipocine Inc.?
The SEC file number for Lipocine Inc. is 001-36357.
From the Filing
0001493152-24-043670.txt : 20241105 0001493152-24-043670.hdr.sgml : 20241105 20241105163736 ACCESSION NUMBER: 0001493152-24-043670 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20241105 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241105 DATE AS OF CHANGE: 20241105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lipocine Inc. CENTRAL INDEX KEY: 0001535955 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 990370688 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36357 FILM NUMBER: 241428092 BUSINESS ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 BUSINESS PHONE: 801 994 7383 MAIL ADDRESS: STREET 1: 675 ARAPEEN DRIVE, SUITE 202 CITY: SALT LAKE CITY STATE: X1 ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: MARATHON BAR CORP DATE OF NAME CHANGE: 20111130 8-K 1 form8-k.htm false 0001535955 0001535955 2024-11-05 2024-11-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): November 5, 2024       LIPOCINE INC.   (Exact name of registrant as specified in its charter)   Commission File No. 001-36357   Delaware   99-0370688 (State or other jurisdiction of incorporation)   (IRS Employer Identification Number)   675 Arapeen Drive , Suite 202 Salt Lake City , Utah 84108 (Address of principal executive offices) (Zip Code)   Registrant’s telephone number, including area code: (801) 994-7383   Former name or former address, if changed since last report: Not Applicable   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13©(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   LPCN   The NASDAQ Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 8.01 Other Events   On Tuesday November 5, 2024, key opinion leader Dr. Frank Greenway presented a poster entitled “Oral LPCN 2401 Reduces Fat Mass and Increases Lean Mass in Men with Obesity” at the Obesity Society’s Annual Obesity Week® conference in San Antonio, Texas. The poster is presented as Exhibit 99.1 and is incorporated herein by reference.   Item 9.01 Financial Statements and Exhibits.   (d) Exhibits   The following exhibits are filed with this report:   Exhibit N